Cohance Lifesciences FY26 Annual Earnings Summary

Two large commercial products faced earlier-than-expected volume recalibration due to patent expiry and inventory normalization; similar risks exist for other mature products.

The Nacharam formulation site received a warning letter; US shipments remain suspended, and remediation may take time, impacting ~₹55 crore in deferred shipments.

Two large commercial molecules under destocking may not return as expected; management declined to quantify value, creating uncertainty.

Historical reliance on a few molecules led to revenue volatility; diversification is improving but still a risk.

Two large commercial molecules are experiencing destocking, impacting pharma CDMO revenue growth. The destocking is expected to last the full year.

Potential US tariffs on pharma intermediates could impact exports, though management noted current FOB terms and customer willingness to absorb tariffs.

Slower decision-making and contract renewals due to biotech funding constraints have muted subsidiary performance and ADC near-term demand.

Management acknowledged that the pace of commercial ramp-up has been slower than anticipated due to customer launch sequencing and cautious initial scale.

Geopolitical tensions have increased freight and raw material costs, expected to impact gross margins by 100-150 bps in Q1 FY27.

NJ Bio's US facility expansion and bio conjugation capabilities will take >2 years to reach breakeven, delaying consolidated margin recovery.

Ongoing one-time expenses (ESOP, professional fees) are distorting EBITDA margins, with no clear timeline for normalization.

The oligonucleotide and bio-conjugation expansions are on schedule but any delays could impact revenue contribution from niche technologies.